Listed

TherapeuticsMD, Inc.: Form 10-K for the period ended Dec 31, 2019

Filed with the SEC on Feb 24, 2020 and accepted by EDGAR at Feb 24, 2020, 16:18 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2019-10-01 to 2019-12-31$15.9mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue12 months2019-01-01 to 2019-12-31$49.6mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue12 months2019-01-01 to 2019-12-31$6.3mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2019-10-01 to 2019-12-31$13.0mus-gaap:GrossProfit
Gross profit12 months2019-01-01 to 2019-12-31$43.3mus-gaap:GrossProfit
Research and development12 months2019-01-01 to 2019-12-31$19.8mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative12 months2019-01-01 to 2019-12-31$174.1mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income12 months2019-01-01 to 2019-12-31−$151.2mus-gaap:OperatingIncomeLoss
Interest expense12 months2019-01-01 to 2019-12-31$17.4mus-gaap:InterestExpense
Net income3 months2019-10-01 to 2019-12-31−$49.4mus-gaap:NetIncomeLoss
Net income12 months2019-01-01 to 2019-12-31−$176.1mus-gaap:NetIncomeLoss
Diluted EPS3 months2019-10-01 to 2019-12-31−$0.19us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS12 months2019-01-01 to 2019-12-31−$0.72us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow12 months2019-01-01 to 2019-12-31−$165.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2019-01-01 to 2019-12-31$2.5mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2019-12-31$160.8mus-gaap:Cash
Current assetsAt period end2019-12-31$208.4mus-gaap:AssetsCurrent
Total assetsAt period end2019-12-31$266.0mus-gaap:Assets
Current liabilitiesAt period end2019-12-31$53.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-12-31$256.8mus-gaap:Liabilities
Long-term debtAt period end2019-12-31$194.6mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2019-12-31$9.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001387131-20-002086. Last ingested by Listed: Nov 14, 2026, 19:24 ET. Listed shows no prices and gives no investment advice.